High homocysteine levels predict the recurrence of atrial fibrillation after successful electrical cardioversion

International Heart Journal

Volumn 51, Issue 1, 2010, Pages 30-33

  Naji, Franjo ^a   Suran, David ^a   Kanic, Vojko ^a   Vokac, Damijan ^a   Sabovic, Miso ^b  

^a UNIVERSITY MEDICAL CENTRE MARIBOR   (Slovenia)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

Atrial fibrillation; Cardioversion; Homocysteine

Indexed keywords

AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HOMOCYSTEINE; PROPAFENONE; SOTALOL;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CARDIOVERSION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT DISEASE; RETROSPECTIVE STUDY; SINUS RHYTHM; THYROID DISEASE;

AGED; ATRIAL FIBRILLATION; ELECTRIC COUNTERSHOCK; FEMALE; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RECURRENCE; RETROSPECTIVE STUDIES;

EID: 76749151811     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.51.30     Document Type: Article

References (19)

1. Anné W, Willems R, Holemans P, et al. Self-terminating AF depends on electrical remodeling while persistent AF depends on additional structural changes in a rapid atrially paced sheep model. J Mol Cell Cardiol 2007; 43: 148-58.
2. Okamura Y, Watanabe I, Ashino S, et al. Electrophysiological properties of the atrium after cardioversion of chronic atrial fibrillation: relation to the plasma brain natriuretic peptide level. Int Heart J 2007; 48: 485-96.
3. Arndt M, Lendeckel U, Röcken C, et al. Altered expression of ADAMs (A Disintegrin And Metalloproteinase) in fibrillating human atria. Circulation 2002; 105: 720-5.
4. Nakano Y, Niida S, Dote K, et al. Matrix metalloproteinase-9 contributes to human atrial remodeling during atrial fibrillation. J Am Coll Cardiol 2004; 43: 818-25.
5. Bescond A, Augier T, Chareyre C, Garçon D, Hornebeck W, Charpiot P. Influence of homocysteine on matrix metalloproteinase-2: activation and activity. Biochem Biophys Res Commun 1999; 263: 498-503.
6. Moshal KS, Singh M, Sen U, et al. Homocysteine-mediated activation and mitochondrial translocation of calpain regulates MMP-9 in MVEC. Am J Physiol Heart Circ Physiol 2006; 291: H2825-35.
7. Whincup PH, Refsum H, Perry IJ, et al. Serum total homocysteine and coronary heart disease: prospective study in middle aged men. Heart 1999; 82: 448-54.
8. Boysen G, Brander T, Christensen H, Gideon R, Truelsen T. Homocysteine and risk of recurrent stroke. Stroke 2003; 34: 1258-61.
9. Marcucci R, Berti I, Cecchi E, et al. Hyperhomocysteinemia and vitamin B6 deficiency: new risk markers for nonvalvular atrial fibrillation? Am Heart J 2004; 148: 456-61.
10. Shimano M, Inden Y, Tsuji Y, et al. Circulating homocysteine levels in patients with radiofrequency catheter ablation for atrial fibrillation. Europace 2008; 10: 961-6.
11. Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114: e257-354.
12. Guéant-Rodriguez RM, Juillière Y, Nippert M, et al. Left ventricular systolic dysfunction is an independent predictor of homocysteine in angiographically documented patients with or without coronary artery lesions. J Thromb Haemost 2007; 5: 1209-16.
13. Tanabe Y, Kawamura Y, Sakamoto N, Sato N, Kikuchi K, Hasebe N. Blood pressure control and the reduction of left atrial overload is essential for controlling atrial fibrillation. Int Heart J 2009; 50: 445-56.
14. Cai BZ, Gong DM, Liu Y, et al. Homocysteine inhibits potassium channels in human atrial myocytes. Clin Exp Pharmacol Physiol 2007; 34: 851-5.
15. Suematsu N, Ojaimi C, Kinugawa S, et al. Hyperhomocysteinemia alters cardiac substrate metabolism by impairing nitric oxide bioavailability through oxidative stress. Circulation 2007; 115: 255-62.
16. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-3.
17. Tsai MY, Bignell M, Scwichtenberg K, Hanson NQ. High prevalence of a mutation in the cystathionine beta-synfhase gene. Am J Hum Genet 1996; 59: 1262-7.
18. Olszewski AJ, Szostak WB, Bialkowska M, Rudnicki S, Mc-Cully KS. Reduction of plasma lipid and homocysteine levels by pyridoxine, folate, cobalamin, choline, riboflavin, and troxerutin in atherosclerosis. Atherosclerosis 1989; 75: 1-6.
19. Chua S, Wu CJ, Chang HW, et al. Impact of elevated plasma total homocysteine concentration on coronary atherosclerosis in Chinese patients with acute myocardial infarction undergoing primary coronary intervention. Int Heart J 2005; 46: 181-93.